Skip to content

Compare methods

Compare source explanations, strengths, limitations and references for up to four methods.

8 results
Criterion Adaptive Competing Risks Analysis Adaptive Trial Design Survival Analysis
Overview
  • Adaptive competing risks analysis combines the Fine-Gray subdistribution hazard framework — which models the cumulative incidence of one cause of failure in the presence of other mutually exclusive causes — with adaptive or group-sequential interim monitoring rules. This allows a clinical trial or observational study to be modified mid-course (e.g., sample size reassessment, early stopping) based on accumulating competing-risk data while maintaining pre-specified type I error control.
  • An adaptive trial design allows pre-specified modifications to the trial based on interim data—such as sample size re-estimation, stopping for futility or efficacy, dropping ineffective arms, or shifting randomization ratios toward better-performing treatments. Developed systematically in the 1990s–2000s by statisticians like Pocock and Jennison, and formalized by the FDA in 2019, adaptive designs accelerate drug development, reduce exposure to ineffective treatments, and improve efficiency without inflating false-positive rates when properly executed.
  • Survival analysis is a collection of statistical methods for modeling time from a defined starting point until an event of interest occurs (disease, recovery, death, equipment failure). Kaplan and Meier's nonparametric estimator (1958) and David Cox's proportional hazards model (1972) jointly enabled analysis of censored data—individuals whose event times are unknown because they left the study or were still event-free at follow-up. Indispensable in oncology, cardiology, infectious disease research, engineering reliability, and any field where time-to-event matters.
Use and interpretation
  • Use adaptive competing risks analysis when (1) the primary outcome is a time-to-event endpoint subject to mutually exclusive competing events (e.g., disease-specific death alongside all-cause mortality or non-fatal events), (2) uncertainty at the design stage makes mid-course adaptations valuable (e.g., uncertain event rates, effect size, or accrual), and (3) the study is large enough — typically a multi-site randomized trial or registry study — to justify the infrastructure for interim monitoring. Do NOT use when (a) competing events are negligible or all-cause mortality is the only endpoint (standard adaptive survival analysis suffices), (b) the sample is too small for interim monitoring to yield meaningful conditional power estimates, or (c) the adaptive rules cannot be pre-specified and locked before unblinding, which would invalidate type I error control.
  • Use adaptive designs when: (1) early signals of efficacy/futility are expected (e.g., efficacy might emerge within 6 months), (2) sample size is uncertain and could be refined by interim data, (3) multiple treatment arms are tested and some may be clearly inferior, (4) ethics demand minimizing exposure to ineffective treatments, (5) development timelines are critical (e.g., orphan drugs, oncology), (6) resources are limited (adaptive designs reduce sample size or duration), (7) prior knowledge is uncertain (interim data refine assumptions about effect size, dropout rate, etc.), (8) seamless phase II/III integration is desired (combining dose-finding with efficacy testing).
  • Use survival analysis when the outcome of interest is time to event and data contain censoring. Oncology: comparing survival between treatment arms (standard randomized trials). Cardiology: analyzing time to cardiovascular events (MI, stroke) in cohort studies. Infectious disease: time from infection to recovery or progression. Medical implants: device failure or replacement time. Industrial engineering: time to equipment failure (reliability analysis). Any longitudinal study with staggered entry and/or early withdrawal can use survival methods. If no censoring exists (all participants followed to completion), simpler methods (t-test, logistic regression) suffice, though survival analysis remains valid.
Level of measurement
  • Time-to-event data with multiple mutually exclusive failure types; censored observations
Strengths
  • Correctly models the probability of failure from a specific cause without the bias introduced by treating competing events as independent censoring.
  • The adaptive layer allows sample size reassessment or early stopping, improving efficiency and reducing exposure of participants to an inferior treatment.
  • Maintains strict type I error control through pre-specified alpha-spending functions even when the study design is modified mid-course.
  • Produces clinically interpretable outputs — cumulative incidence functions — that directly inform treatment decisions better than cause-specific hazard ratios alone.
  • Applicable to both randomized clinical trials and large observational registry studies with event-time data.
  • Efficiency: reduced sample size and shorter trial duration if interim evidence is conclusive, saving time and cost.
  • Ethics: Response-Adaptive Randomization minimizes exposure to inferior arms; futility stopping prevents prolonged enrollment when efficacy is unlikely.
  • Flexibility: adaptations can address emerging uncertainties without sacrificing statistical rigor, if pre-specified.
  • Information-driven: interim data inform resource allocation and arm selection, improving trial design dynamically.
  • Regulatory acceptance: FDA and EMA accept adaptive designs when properly pre-specified and controlled for Type I error; increasingly standard in modern drug development.
  • Correctly handles censored data without bias: exploits information from censored individuals (follow-up time) rather than discarding them.
  • Flexibly estimates both univariate (Kaplan-Meier) and multivariable (Cox) associations; baseline covariates are adjusted without assuming linear effects.
  • Hazard ratios are intuitive: single metric comparing event rates, easily interpreted by clinicians and communicated in publications.
  • Nonproportional hazards detectable: assumption diagnostics alert researchers when treatment effects change over time; alternative models (AFT, stratification, time-varying coefficients) address violations.
  • Risk stratification: predicted survival curves enable clinicians to quantify prognosis and individualize treatment decisions based on baseline characteristics.
Limitations
  • The subdistribution hazard ratio from the Fine-Gray model does not have as direct a biological interpretation as the cause-specific hazard ratio; it mixes the effects of covariates on occurrence and on competing event survival.
  • Requires pre-specification of all adaptive rules, alpha-spending functions, and interim look schedules before data unblinding — post-hoc adaptations invalidate inference.
  • Interim data review by an unblinded statistician or independent data monitoring committee adds logistical and regulatory complexity.
  • Small to moderate sample sizes may not provide sufficient conditional power at interim looks to make adaptation decisions reliable.
  • Complexity: adaptive designs require sophisticated statistical planning, interim analysis infrastructure, and careful execution. Blinding and data management become challenging.
  • Inflation of Type I error if done wrong: post-hoc adaptations or ignorance of sequential testing methods inflate false positives. Rigorous pre-specification is non-negotiable.
  • Effect size inflation from early stopping: if efficacy stopping boundary is crossed, the observed effect size at that point is likely inflated (optimism bias). Final trial effect may be smaller than interim estimate.
  • Comparability across adaptations: if arms are dropped or randomization ratios shift, comparability between new and original participants may be compromised. Subgroup analyses required.
  • Regulatory and operational overhead: adaptive designs require pre-registration, detailed statistical plans, interim analysis expertise, and communication with regulators. Not all settings can support this.
  • Proportional hazards assumption: Cox model assumes constant treatment effect over time; violations require alternative methods (accelerated failure time models, time-varying coefficients, stratification).
  • Sparse data at long follow-up times: survival estimates become less stable as participants are censored; confidence intervals widen, limiting inference for late-event prediction.
  • Administrative censoring: if censoring is related to prognosis (informative censoring), standard methods are biased; requires joint modeling or inverse probability weighting.
  • Assumes conditional independence given covariates; unmeasured confounding threatens causal inference, particularly in observational studies.
  • Small event counts reduce power and stability of Cox coefficients; generally need ≥10 events per covariate for stable estimation.
Common pitfalls
  • Treating competing events as independent censoring in a standard Kaplan-Meier or Cox model — this overestimates the cumulative incidence of the primary event and inflates apparent treatment benefits.
  • Conducting unplanned interim analyses outside the pre-specified alpha-spending framework, which inflates the type I error rate and can invalidate regulatory submissions.
  • Ignoring the competing events entirely when reporting results — a treatment that reduces cancer death but increases cardiovascular death may appear beneficial if only one endpoint is shown.
  • Using adaptive rules that depend on the unblinded treatment effect without an appropriate combination test, leading to invalid p-values and confidence intervals at the final analysis.
  • Confusing cumulative incidence functions with (1 − Kaplan-Meier) estimator values; only the CIF is the correct estimator when competing risks are present.
  • Unblinded interim analyses leading to operational bias: if trial team knows treatment assignments at interim, decisions may be subconsciously swayed. Use independent Data Monitoring Committees (DMC) and maintain blinding to identifiable arm labels.
  • Post-hoc adaptations: if adaptation rules are not pre-specified and written before unblinding, that is p-hacking. Adaptive design validity rests on pre-specification.
  • Ignoring multiple testing: conducting interim looks without adjusting p-value thresholds inflates Type I error. Always use sequential testing methods (alpha-spending, group-sequential design).
  • Over-interpreting early signals: interim point estimates are noisy. Wide confidence intervals at interim should temper confidence in effect direction or magnitude. Do not over-commit to adaptations based on unstable estimates.
  • Loss of generalizability from arm dropping: if an arm is dropped mid-trial and final results omit its participants, the trial becomes unrepresentative. Careful documentation and sensitivity analyses required.
  • Treating censored data as failures: incorrectly coding censored times as events biases hazard estimates downward and hazard ratios toward 1.
  • Failing to check proportional hazards assumption: plot Schoenfeld residuals or test time-varying coefficients; violation invalidates Cox model interpretation.
  • Omitting censoring indicators: must explicitly code event status (1 = occurred, 0 = censored); wrong coding leads to incorrect likelihood and estimates.
  • Comparing groups with unequal follow-up times without adjustment: survival analysis accounts for varying follow-up, but naïve comparison of event counts is biased.
  • Overfitting with too many covariates relative to events: Cox regression with many predictors and few events produces unstable, unreliable estimates; use penalized regression (ridge, lasso) or dimensionality reduction.
  • Using median follow-up as justification for omitting survival analysis: median follow-up describes the data but does not replace proper analysis of individual follow-up times.
Introduced by
  • Fine & Gray (subdistribution hazard, 1999); adaptive extensions by Beyersmann, Schumacher and colleagues
  • Stephen Pocock, Christopher Jennison, and statistical methodologists; FDA formalized guidance 2019
  • Edward L. Kaplan and Paul Meier
Year
  • 1999 (foundational Fine-Gray model); adaptive extensions 2000s–2010s
  • 1990s-2000s
  • 1958